"We all want to go to Tahiti. If we have to go to Coronado, we tell ourselves it's as good."
– Christian Rommel, Intellikine Inc.'s chief scientific officer, explaining that creating isoform selective PI3K inhibitors is very hard, and if you can't do it, you start saying you don't need them
"Anybody working on a drug needs to think about how they are going to address the companion diagnostics side of it."
– Pascale Witz, president and CEO of GE Healthcare's medical diagnostics business
"Development costs become onerous very quickly in this game."
– Jay Luly, president and CEO of Enanta Pharmaceuticals Inc., on the need to partner in HCV
"We don't talk about curative too often."
– Mark Edwards, managing director of BioScience Advisors Inc., on the potential for HCV treatments to significantly improve outcomes